Table 2.

Objective response and disease control rate (per iRANO) in the study population

	Overall population (n=54)	Cohort-1 (n=27)	Cohort-2 (n=27)
Confirmed objective response, n(%)	15 (27.8%)	9 (33.3%)	6 (22.2%)
Complete response	2 (3.7%)	1 (3.7%)	1 (3.7%)
Partial response	13 (24.1%)	8 (29.6%)	5 (18.5%)
Stable disease, n(%)	15 (27.8%)	8 (29.6%)	7 (25.9%)
Progressive disease, n(%)	24 (44.4%)	10 (37.0%)	14 (51.9%)
Disease control rate, n(%)	30 (55.6%)	17 (63.0%)	13 (48.1%)
Median duration of response, weeks	18.0 (range 6.0–83.1)	17.9 (range 6.0–83.1)	19.0 (range 8.0–38.0)
Median time to response, weeks	6.0 (range 4.7–18.0)	6.0 (range 5.1–18.0)	5.9 (range 4.7–8.0)

iRANO, immunotherapy response assessment for neuro-oncology.